An Open-Label, Phase 1, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Trial Profile

An Open-Label, Phase 1, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs M 9831 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2017 Planned End Date changed from 1 Dec 2018 to 17 Nov 2017.
    • 14 Nov 2017 Planned primary completion date changed from 1 Sep 2018 to 17 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top